Technical Analysis for FDMT - 4D Molecular Therapeutics, Inc.

Grade Last Price % Change Price Change
B 19.09 3.98% 0.73
FDMT closed up 1.55 percent on Friday, June 2, 2023, on 72 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 3.98%
Bollinger Band Squeeze Range Contraction 5.59%
Shooting Star Candlestick Bearish 3.98%
Lizard Bearish Bearish Day Trade Setup 3.98%
Bollinger Band Squeeze Range Contraction 3.98%
Doji - Bearish? Reversal 3.98%
BB Squeeze + Upper Band Touch Range Contraction 3.98%
Upper Bollinger Band Touch Strength 3.98%
Crossed Above 20 DMA Bullish 3.86%
Crossed Above 50 DMA Bullish 3.86%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 5% about 2 hours ago
60 Minute Opening Range Breakout about 3 hours ago
Up 3% about 3 hours ago
Rose Above Upper Bollinger Band about 3 hours ago
Up 2% about 3 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


4D Molecular Therapeutics, Inc. Description

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Biology Emerging Technologies Antibodies Molecular Biology Gene Therapy Medical Genetics Gene Delivery Fabry Disease Gene Therapy Of The Human Retina Gene Therapy Products

Is FDMT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.49
52 Week Low 5.32
Average Volume 537,577
200-Day Moving Average 16.10
50-Day Moving Average 17.75
20-Day Moving Average 17.77
10-Day Moving Average 18.06
Average True Range 1.20
RSI (14) 52.83
ADX 9.44
+DI 24.47
-DI 21.13
Chandelier Exit (Long, 3 ATRs) 16.12
Chandelier Exit (Short, 3 ATRs) 19.44
Upper Bollinger Bands 18.80
Lower Bollinger Band 16.74
Percent B (%b) 0.79
BandWidth 11.55
MACD Line 0.07
MACD Signal Line 0.01
MACD Histogram 0.0571
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.46
Resistance 3 (R3) 19.38 18.95 19.27
Resistance 2 (R2) 18.95 18.67 18.98 19.21
Resistance 1 (R1) 18.65 18.50 18.80 18.73 19.15
Pivot Point 18.22 18.22 18.29 18.25 18.22
Support 1 (S1) 17.92 17.94 18.07 18.00 17.57
Support 2 (S2) 17.49 17.77 17.52 17.51
Support 3 (S3) 17.19 17.49 17.45
Support 4 (S4) 17.27